DRUG THERAPY AND PREGNANCY: UNKNOWN RISKS LEAD TO HARD CHOICES [REDACTED VERSION]

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Goldstein, Lori M.	en_US
dc.date.accessioned	2012-07-06T21:39:31Z
dc.date.issued	2001	en_US
dc.identifier.citation	DRUG THERAPY AND PREGNANCY: UNKNOWN RISKS LEAD TO HARD CHOICES [REDACTED VERSION] (2001 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965596
dc.description.abstract	This paper is a proposal to improve the quality of information available to pregnant patients in selecting treatment options. By providing drug companies with extended grants of exclusivity, the FDA has the ability to empower pregnant women to take control of their health and make informed decisions. Granted post-marketing surveillance will always catch ADRs at a later stage of the game than pre-market clinical trials, but in the case of pregnant women; where we must concern ourselves with potential harms to a future sentient child - increased rigor in the method and quantity of post marketing surveillance techniques seems like the only way to go.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	FDA	en
dc.subject	pregnancy	en
dc.subject	drug testing	en
dc.title	DRUG THERAPY AND PREGNANCY: UNKNOWN RISKS LEAD TO HARD CHOICES [REDACTED VERSION]	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-07-06T21:39:31Z